Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Juli 2025 07:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline...
27. Mai 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary...
22. Mai 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn to Participate in the Jefferies Global Healthcare Conference in June

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary...
20. Mai 2025 16:01 ET | Quelle: Avalyn Pharma Inc.

Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025

Topline results for AP02 (inhaled nintedanib) confirmed safety and tolerability with limited systemic exposure and substantially improved lung exposure compared to oral nintedanib AP01 (inhaled...
06. Mai 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference

Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company’s Five Poster Presentations 4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled...
10. April 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn to Participate in Upcoming Investor Conference in April

CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
01. April 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis

Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data...
25. Februar 2025 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn to Participate in TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
17. Dezember 2024 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
25. November 2024 08:00 ET | Quelle: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...

Vorherige Seite

Nächste Seite